TD Cowen initiated coverage of Freenome with a Buy rating and a $17 price target, citing differentiated liquid biopsy chemistry and commercial momentum through partnerships with Abbott and Roche. The analyst pointed to Freenome’s multi-cancer early detection roadmap and a projected sales ramp tied to additional blood-based screening assays beyond its first commercial product. Cowen’s note highlighted Freenome’s Abbott Cancer Diagnostics deal for SimpleScreen CRC and described partnership-backed plans that could support scaling across lung cancer screening and MCED. At the same time, the bank flagged risks around high cash burn, the scale of projected capital needs, and limited visibility on key pipeline products. For the market, the initiation adds a fresh pro-coverage anchor for MCED expectations while reinforcing the near-term need to convert early commercialization into repeatable assay adoption.